Key Takeaways Revolution Medicines reported a Q3 loss of $1.61 per share, missing the expected $1.39 loss.R&D expenses jumped 73% year over year to $263M, driven by higher clinical and manufacturing costs.The company's lead drug daraxonrasib is in two late-stage studies, with a key data readout expected in 2026.Revolution Medicines (RVMD) reported a third-quarter 2025 loss of $1.61 per share, wider than the Zacks Consensus Estimate of a loss of $1.39. The company had incurred a loss of 94 cents in the year- ...